Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases

Despite per-patient annual treatment costs ranging up to several hundreds of thousands of euros for some OMPs, per-capita spending for OMPs is relatively small. In this study an inverse relationship between prevalence and annual treatment costs was found.